Edison issues report on The Biotech Growth Trust (BIOG)

London, UK, 5 September 2025

Edison issues report on The Biotech Growth Trust (BIOG)

Edison issues report on The Biotech Growth Trust (LSE: BIOG)

The Biotech Growth Trust (BIOG) is managed Geoff Hsu and Josh Golomb at leading global healthcare specialist OrbiMed. The trust provides access to the rapidly evolving biotech sector, seeking long-term capital appreciation by investing in high-quality biotech stocks across the market cap spectrum, with a bias towards smaller, emerging biotech companies. Since Q121, the trust has faced significant performance headwinds in what has been the industry’s largest and most prolonged drawdown. However, the managers remain confident that a stark disconnect exists between current valuations and the favourable fundamentals of the biotech sector. With industry innovation at an all-time high, a generally supportive regulatory environment and major pharma companies looking to bolster their pipelines ahead of a major patent cliff, which should spur M&A activity, now may be an opportune time for investors to consider the biotech sector.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

[email protected]

+44 (0)20 3077 5700

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

X  www.x.com/edison_inv_res

YouTube www.youtube.com/edisonitv